CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Ramipril/felodipine extended release

Last Updated: June 22, 2006
Result type: Reports
Project Number: SR0067-000
Product Line: Reimbursement Review

Generic Name: Ramipril/felodipine extended release

Brand Name: Altace Plus Felodipine

Manufacturer: Sanofi-Aventis Canada Inc.

Therapeutic Area: Hypertension

Indications: Hypertension

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 15, 2006

Recommendation Type: Do not list